Program
Pneumococcal Conjugate Vaccine
Also written as “Multivalent”, “Pneumococcal Conjugate Vaccine (V114)” and “Pneumococcal conjugate vaccine”.
Its studies are mostly in Pneumococcal Infections, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizer | 20 open or running | phase 2since Apr 11, 2018 | Apr 11, 2018 | none ahead |
| LG Chem | 10 open or running | phase 1since Sep 2, 2016 | Sep 2, 2016 | none ahead |
| Merck | 10 open or running | phase 2since Dec 27, 2011 | Dec 27, 2011 | none ahead |
| Sanofi | 10 open or running | phase 1since Nov 18, 2024 | Nov 18, 2024 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 27, 2011First study: phase 2 study in Pneumococcal InfectionsNew to MerckMerck · NCT01513551 · 692 enrolled
- Sep 2, 2016LG Chem’s first study: phase 1 study in Pneumococcal InfectionsNew to LG ChemLG Chem · NCT02892812 · 63 enrolled · Korea, Republic of
- Apr 11, 2018Pfizer’s first study: phase 2 study in Pneumococcal InfectionsNew to PfizerPfizer · NCT03512288 · 460 enrolled · United States
- May 25, 2018Phase 2 study in Pneumococcal InfectionsPfizer · NCT03550313 · 565 enrolled · United States
- Nov 18, 2024Sanofi’s first study: phase 1 study in Pneumococcal ImmunizationNew to SanofiSanofi · NCT06698198 · 175 enrolled · United States
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“An active immunizing vaccine used to prevent infection by the bacterium Streptococcus pneumoniae”NCIt, by rule
“Pneumococcal Conjugate Vaccine”name, by rule
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06698198Pneumococcal Immunization · United States | 1 | Completed | Sanofi | Sep 30, 2019 | 175 |
| NCT03550313Pneumococcal Infections · United States | 2 | Terminated | Pfizer | Nov 5, 2020 | 565 |
| NCT03512288Pneumococcal Infections · United States | 2 | Completed | Pfizer | Feb 11, 2020 | 460 |
| NCT02892812Pneumococcal Infections · Korea, Republic of | 1 | Completed | LG Chem | Nov 2016 | 63 |
| NCT01513551Pneumococcal Infections | 2 | Completed | Merck | Feb 15, 2013 | 692 |
How it is read
Names in the registry
- “Multivalent”, 2 entries
- “Pneumococcal Conjugate Vaccine”, 1 entry
- “Pneumococcal Conjugate Vaccine (V114)”, 1 entry
- “Pneumococcal conjugate vaccine”, 1 entry
Conditions, from the studies’ own filings
- Pneumococcal Infections, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.